Infektionen unter antirheumatischer Therapie

Literatur
1 Au K, Reed G, Curtis JR et al. Corona Investigators. High disease activity is associated with an increased risk of infection in patients with rheumaotid arthritis. Ann Rheum Dis 2011; 70: 785-791
2 Cornberg M, Protzer U, Petersen J et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline. Z Gastroenterol 2011; 49: 871-930
3 Crowson CS, Hoganson DD, Fitz-Gibbon PD et al. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2847-2855
4 Curtis JR, Xie F, Chen L et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res 2012; 64: 1480-1489
5 Diel R, Hauer B, Loddenkemper R et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen. Pneumologie 2009; 63: 329-334 und Z Rheumatol 2009; 68 411-416
6 Dixon WG, Kezouh A, Bernatsky S et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis 2011; 70: 956-960
7 Droz N, Gilardin L, Cacoub P et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res 2013; 65: 1504-1514
8 Fanouriakis A, Vassilopoulos D, Repa A et al. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology 2014; 53: 195-196
9 Goldacker S, Gause AM, Warnatz K. Kommission Pharmakotherapie der DGRh. Vaccination in adult patients with chronic inflammatory rheumatic diseases. Z Rheumatol 2013; 72: 690-694
10 Hazlewood GS, Naimark D, Gardam M et al. Prophylaxis for latent tuberculosis infection prior to anti-TNF therapy in low-risk elderly patients with rheumatoid arthritis: A decision analysis. Arthritis Care Res 2013; 65: 1722-1731
11 Kapetanovic MC, Kristensen LE, Saxne Aktas T et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014; 16: R2
12 Kapetanovic MC, Saxne T, Jönsson G et al. Rituximab and abatacept but not Tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013; 15: R171
13 Kim PS, Ho GY, Prete PE et al. Safety and efficacy of abatacept In eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 2012; 64: 1265-1268
14 Kleinert S, Tony HP, Krueger K et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis 2012; 71: 1791-1795
15 Krause A, Krüger K. Pneumokokkenimpfung bei immunsupprimierten Patienten. Z Rheumatol 2013; 72: 942-946
16 Mariette X, Baron G, Tubach F et al. Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic anti-tuberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012; 71: 1783-1790
17 Matulis G, Juni P, Villiger PM et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon {gamma} assay. Ann Rheum Dis 2008; 67: 84-90
18 Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
19 Warnatz K, Goldacker S, Gause AM. Kommission Pharmakotherapie der DGRh [Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology]. Z Rheumatol 2013; 72: 687-689
20 Winthrop KL, Weinblatt ME, Daley CL. You can’t always get what you want, but if you try sometimes (with two tests – TST and IGRA – for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71: 1757-1760
21 Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34
22 Zink A, Manger B, Kaufmann J et al. Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 2013; [Epub ahead of print]